Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Want to see ACXP full AI Analyst Report?
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-28.06% Downside)
Action:Reiterated
Date:05/14/26
Overall score reflects weak fundamentals (pre-revenue, ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). These are partially offset by a constructive earnings update highlighting favorable FDA guidance, planned clinical progression, and IP strength, though funding needs remain a key risk.
Positive Factors
Clinical efficacy (Phase II)
Robust Phase II results with ~96% cure and no observed 1-month recurrences among cured patients signal a durable clinical profile that can differentiate ibezapolstat in CDI. Strong early efficacy supports regulatory discussions, informs confirmatory evidence and enhances the likelihood of adoption if replicated in larger trials.
Negative Factors
Limited cash for Phase III
A $9.3M cash balance is structurally insufficient to fund registrational Phase III studies, creating near-term financing dependency. This increases dilution and execution risk, could delay trial initiation or completion, and forces management to prioritize fundraising over operations and longer-term strategic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy (Phase II)
Robust Phase II results with ~96% cure and no observed 1-month recurrences among cured patients signal a durable clinical profile that can differentiate ibezapolstat in CDI. Strong early efficacy supports regulatory discussions, informs confirmatory evidence and enhances the likelihood of adoption if replicated in larger trials.
Read all positive factors
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.12M
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)―
Beta (1Y)-0.43
Revenue GrowthN/A
EPS Growth68.70%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.91
Shares Outstanding4,297,738
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.81
Forecast
1Y Price Target
$17.00Price Target Upside511.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.16
Revenue Forecast (FY)N/A
Acurx Pharmaceuticals Business Overview & Revenue Model
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that ha...
How the Company Makes Money
As a clinical-stage company, Acurx does not have established, recurring product revenue from marketed drugs. Its cash inflows have historically been driven primarily by financing activities (e.g., issuing equity) rather than operating revenue; spe...
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.Positive Updates
Strong Phase II Efficacy and No Recurrence in Cured Patients
Ibezapolstat Phase II showed a ~96% clinical cure rate and 0% recurrence among cured patients at 1 month (25/25 recurrence-free). In a subset, 5/5 patients observed out to 3 months remained recurrence-free, supporting the drug's potential to treat acute CDI and reduce recurrence.
Negative Updates
Limited Cash for Late-Stage Development
Ending cash of $9.3M, while improved, is modest relative to the capital-intensive requirements of Phase III registrational trials; management continues to pursue additional funding and initiatives to support Phase III but substantial additional capital is likely needed.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Phase II Efficacy and No Recurrence in Cured Patients
Ibezapolstat Phase II showed a ~96% clinical cure rate and 0% recurrence among cured patients at 1 month (25/25 recurrence-free). In a subset, 5/5 patients observed out to 3 months remained recurrence-free, supporting the drug's potential to treat acute CDI and reduce recurrence.
Read all positive updates
Company Guidance
The call highlighted the FDA’s new final C. difficile guidance that formalizes a default one‑trial pathway—allowing a single adequate and well‑controlled pivotal trial supported by “confirmatory” evidence (mechanistic/in‑vitro MIC and killing data, molecular mechanism, animal efficacy models, microbiome data, etc.) to meet substantial evidence of effectiveness; Acurx has an FDA meeting planned to align on this, and is initiating an open‑label rCDI pilot of 20 multiply‑recurrent patients (≥3 episodes in the prior 12 months) with a planned interim look at ~10 patients and first patient targeted around August, followed by a planned active‑controlled Phase III and potential LPAD submission for rCDI; the company will use its Phase II data as part of the confirmatory package (Phase II reported ~96% cure rate, 25/25 cured patients free of recurrence at 1 month and 5/5 free at 3 months), will follow the standard 1‑month recurrence endpoint (and extend follow‑up to 8 weeks/56 days to compare to live‑biologic comparators VOWST and REBYOTA), and reinforced program strength with IP (10 patents, including 5 U.S., with one patent extending to December 2039) and recent financing (cash $9.3M as of March 31, ~ $3.1M raised this quarter; 3,389,106 shares outstanding).Acurx Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.63M | -8.09M | 0.00 | -14.58M | -12.09M | -12.81M |
| Net Income | -7.50M | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
Balance Sheet | ||||||
| Total Assets | 9.54M | 7.69M | 3.86M | 7.71M | 9.38M | 13.25M |
| Cash, Cash Equivalents and Short-Term Investments | 9.25M | 7.56B | 3.71M | 7.47M | 9.11M | 12.96M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.53M | 2.42M | 3.24M | 3.04M | 2.06M | 843.91K |
| Stockholders Equity | 7.01M | 5.27M | 615.12K | 4.67M | 7.32M | 12.41M |
Cash Flow | ||||||
| Free Cash Flow | -6.14M | -6.79B | -10.38M | -9.80M | -7.54M | -5.01M |
| Operating Cash Flow | -6.14M | -6.79B | -10.38M | -9.80M | -7.54M | -5.01M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 10.75M | 10.64B | 6.62M | 8.16M | 3.70M | 14.80M |
Acurx Pharmaceuticals Technical Analysis
Negative
2.78
Price Trends
3.07
Negative
2.68
Negative
3.71
Negative
Market Momentum
-0.23
Negative
38.79
Neutral
24.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 2.78 is above the 20-day moving average (MA) of 2.02, below the 50-day MA of 3.07, and below the 200-day MA of 3.71, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 38.79 is Neutral, neither overbought nor oversold. The STOCH value of 24.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $8.12M | -0.83 | -291.07% | ― | ― | 68.70% | |
43 Neutral | $8.86M | -0.26 | -97.58% | ― | 78.64% | 50.70% | |
42 Neutral | $84.45M | -7.35 | -53.86% | ― | -20.00% | 75.26% | |
41 Neutral | $4.33M | ― | -423.84% | ― | -8.47% | 25.61% | |
39 Underperform | $579.79K | ― | -1302.82% | ― | ― | 99.09% |
* Healthcare Sector Average
ACXP
Acurx Pharmaceuticals
1.89
-6.07
-76.26%
IBIO
Ibio
1.70
0.91
114.38%
WINT
Windtree Therapeutics
0.02
-0.73
-97.73%
BRTX
BioRestorative Therapies
0.17
-1.43
-89.44%
LIXT
Lixte Biotechnology Holdings
5.60
4.34
344.44%
BOLT
Bolt Biotherapeutics
4.61
-1.89
-29.08%
Acurx Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
Positive
Apr 16, 2026
On April 15–16, 2026, Acurx Pharmaceuticals, Inc. entered into agreements for a registered direct offering and concurrent private placement of its securities, raising approximately $2.5 million in upfront gross proceeds and issuing common st...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
Acurx Advances Ibezapolstat Program for Recurrent C. difficile
Positive
Mar 9, 2026
On March 9, 2026, Acurx Pharmaceuticals’ compensation committee approved voluntary 10% base-salary cuts for its top executives and a 10% reduction in cash retainers for non-employee directors, effective April 1, 2026, while leaving bonus tar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.